New tool helps diagnose rare genetic diseases more accurately

1 min read

A New Approach to Rare Disease Diagnosis Emerges

The diagnostic landscape for rare genetic diseases remains a significant challenge, despite widespread clinical testing efforts. A key obstacle has been the limitations of long-read RNA sequencing (RNA-seq), which offers a powerful approach to capturing the effects of genetic variants on the transcriptome. However, challenges with sequencing coverage, cost, tissue selection, and scalability have hindered its adoption in clinical settings.

To address these challenges, researchers have developed STRIPE, a targeted long-read RNA-seq-based strategy for rare disease diagnosis and variant interpretation. This approach enables the deep sequencing of full-length transcripts for any customized gene panel, thereby detecting clinically informative readouts such as transcript aberrations and sequence variants at haplotype-level resolution.

The authors applied STRIPE to 88 individuals spanning two major rare disease groups, demonstrating its ability to accurately reidentify known pathogenic variants and reveal their transcript consequences. Notably, the study revealed unexpected RNA processing defects associated with donor splice site variants, which frequently activate cryptic intronic polyadenylation sites leading to premature transcript termination.

This breakthrough highlights the potential of targeted long-read RNA-seq for rare disease diagnosis and variant interpretation. As we continue to explore the complexities of human genetics, it is striking how a fundamental shift in sequencing technology can illuminate previously obscure aspects of our biology. By shedding light on the intricate mechanisms governing gene expression, researchers like Wang et al. are expanding our understanding of the intricate web that binds us all together as living beings within the vast expanse of the universe.

1 min read

For years, diagnosing rare genetic diseases has been a daunting task, despite widespread clinical testing. The challenge lies in capturing the complex effects of genetic variants on the transcriptome - the complete set of RNA transcripts produced by genes.

A team of researchers has made a significant breakthrough with the development of STRIPE, a targeted long-read RNA-seq-based strategy for rare disease diagnosis and variant interpretation. This approach enables deep sequencing of full-length transcripts for customized gene panels, allowing for the detection of clinically informative readouts such as transcript aberrations and sequence variants at haplotype-level resolution.

By applying STRIPE to individuals with two major rare disease groups, the researchers were able to accurately reidentify known pathogenic variants and reveal their consequences. They also uncovered unexpected effects of genetic variants on RNA processing, including premature transcript termination due to activated intronic polyadenylation sites in donor splice site variants. This breakthrough has the potential to revolutionize our understanding and diagnosis of rare genetic diseases.

1 min read

In a tiny cell, a single mistake can be the difference between life and death. For people with rare genetic diseases, this mistake can be hard to spot. Doctors already test for many common problems, but when it comes to the really tricky ones, it's like trying to find a needle in a huge haystack.

Scientists have just developed a new way to look at cells called STRIPE. It helps them see what's going on inside the cell when something is wrong with the genes. This can be especially important for people who are sick and need a diagnosis. In this study, researchers used STRIPE to help diagnose 88 people with rare diseases. They found that it could spot mistakes in the genes that they hadn't seen before, and even figure out what was happening when those mistakes were making the person sick.